StoryFunding
Retro Biosciences begins raising a $1B Series A, with Sam Altman participating, to take its programs into trials
Retro Biosciences began raising $1B in a Series A with Sam Altman, who had funded its entire $180M seed round. The company aims to extend healthy human lifespan by approximately 10 years and plans trials for age-related diseases including Alzheimer's, leveraging AI protein engineering and epigenetic reprogramming approaches.
- $1B Series A round with Sam Altman participating; Altman previously provided entire $180M seed funding.
- Focus on extending healthy human lifespan by 10 years through gene therapy and cellular rejuvenation.
- Clinical trials planned for age-related diseases including Alzheimer's using improved reprogramming factors.